MEI Pharma, Inc.

381 articles about MEI Pharma, Inc.

• MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344

  4/11/2024

  MEI Pharma, Inc. today reported that the Company’s Board of Directors unanimously agreed on a strategic plan to leverage recent positive voruciclib and ME-344 clinical data to prioritize clinical development of voruciclib while enabling development of a new ME-344 formulation for Phase 1 study.

• MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients

  4/11/2024

  MEI Pharma, Inc. today reported that 25% of evaluable patients with relapsed metastatic colorectal cancer (“mCRC”) in Cohort 1 of the ongoing Phase 1b study evaluating ME-344, an investigational inhibitor of mitochondrial oxidative phosphorylation (“OXPHOS”), in combination with bevacizumab (Avastin®) had no disease progression at Week 16.

• MEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology Forum

  4/10/2024

  MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today announced that David Urso, president and chief executive officer of MEI Pharma, will participate in a fireside chat at the Stifel 2024 Virtual Targeted Oncology Forum on Tuesday, April 16 at 1:30 PM Eastern Time.

• MEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia

  3/26/2024

  MEI Pharma, Inc. (Nasdaq: MEIP) today reported initiation of enrollment in a 12-patient expansion cohort in the ongoing Phase 1 study evaluating voruciclib, an investigational selective oral cyclin-dependent kinase 9 (“CDK9”) inhibitor, in combination with venetoclax (Venclexta®), a B-cell lymphoma 2 (“BCL2”) inhibitor, in relapsed and refractory (“R/R”) acute myeloid leukemia (“AML”) patients.

• MEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational Highlights

  2/13/2024

  MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today reported results for the three and six months ended December 31, 2023, and highlighted recent corporate events.

• MEI Pharma to Present Design of Ongoing Clinical Study Evaluating ME-344 at ASCO GI Cancers Symposium 2024

  1/16/2024

  MEI Pharma, Inc. (Nasdaq: MEIP) today announced the design of the ongoing Phase 1b study of the mitochondrial oxidative phosphorylation (OXPHOS) inhibitor ME-344 in combination with bevacizumab (Avastin®) in refractory metastatic colorectal cancer patients will be presented during a poster session at the 2024 ASCO Gastrointestinal Cancers Symposium to be held January 18 – 20, 2024.

• MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib at ASH2023

  12/11/2023

  MEI Pharma, Inc. announced clinical data from the monotherapy dose escalation stage of the ongoing Phase 1 study evaluating voruciclib, a selective oral cyclin-dependent kinase 9 inhibitor, alone and in combination with venetoclax, a B-cell lymphoma 2 inhibitor, in patients with acute myeloid leukemia or B-cell malignancies, is highlighted in a poster session at the 65th American Society of Hematology Annual Meeting and Exposition.

• MEI Pharma Reports First Quarter Fiscal Year 2024 Results and Operational Highlights

  11/9/2023

  MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today reported results for the quarter ended September 30, 2023 and highlighted recent corporate events.

• MEI Pharma to Present at the Stifel 2023 Healthcare Conference

  11/8/2023

  MEI Pharma, Inc. today announced it will participate in the Stifel 2023 Healthcare Conference.

• MEI Pharma Declares Special Cash Dividend of $1.75 Per Share of Common Stock

  11/6/2023

  MEI Pharma, Inc. announced that pursuant to the previously disclosed cooperation agreement with Anson Funds and Cable Car Capital, the Company’s Board of Directors today declared a special cash dividend of $1.75 per share of common stock, $0.00000002 par value, payable on December 6, 2023 to stockholders of record at the close of business on November 17, 2023.

• MEI Pharma Announces Acceptance of Abstract for Presentation at ASH 2023

  11/2/2023

  MEI Pharma, Inc. will be presented during a poster session at the upcoming 65th American Society of Hematology (ASH) Annual Meeting and Exposition to be held December 9 – 12, 2023.

• MEI Pharma Enters into Agreement with Anson Funds and Cable Car Capital

  11/1/2023

  MEI Pharma, Inc. and Anson Funds and Cable Car Capital announced that they have entered into a cooperation agreement. Key terms of the agreement include: Capital Return to Stockholders.

• MEI Pharma Adopts Limited-Duration Stockholder Rights Plan

  10/2/2023

  MEI Pharma, Inc. announced that its Board of Directors has unanimously approved the adoption of a limited-duration stockholder rights plan under which stockholders will receive rights to purchase a new series of preferred stock in certain circumstances.

• MEI Pharma Reports Fiscal Year 2023 Results and Operational Highlights

  9/26/2023

  MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for its fiscal year ended June 30, 2023.

• MEI Pharma to Report 2023 Fiscal Year End Financial Results and Provide Corporate Overview on September 26, 2023

  9/21/2023

  MEI Pharma, Inc. (NASDAQ: MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that the Company will release its 2023 fiscal year end financial results after the close of the U.S. financial markets on September 26, 2023.

• MEI Pharma Announces First Patient Dosed in Clinical Study Evaluating ME-344 Plus Bevacizumab (AVASTIN®) in Patients with Previously Treated Metastatic Colorectal Cancer

  8/16/2023

  MEI Pharma, Inc. today announced the dosing of the first patient in a Phase 1b study evaluating ME-344 in combination with bevacizumab (AVASTIN®) in patients with previously treated metastatic colorectal cancer.

• Infinity Pharmaceuticals Announces Termination of Merger Agreement with MEI Pharma

  7/24/2023

  Infinity Pharmaceuticals, Inc. announced that it has terminated its previously announced merger agreement providing for the merger with MEI Pharma, Inc. (“MEI”).

• MEI Pharma Announces Results of Special Meeting of Stockholders - July 23, 2023

  7/23/2023

  MEI Pharma, Inc. announced that, based on a count of the votes cast at the Company’s Special Meeting of Stockholders, MEI, by a narrow margin, did not obtain the necessary stockholder votes to approve the merger agreement with Infinity Pharmaceuticals, Inc.

• MEI Pharma Reminds Shareholders to Vote Today FOR the Infinity Transaction

  7/19/2023

  MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”) today reminded shareholders to vote FOR the pending transaction with Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity”) in connection with the Company’s special meeting on July 23, 2023.

• MEI Pharma Postpones Special Meeting of Shareholders - July 13, 2023

  7/13/2023

  MEI Pharma, Inc. announced that it has postponed its special meeting in connection with the proposed transaction with Infinity Pharmaceuticals, Inc. to July 23, 2023, at 10:00 a.m. Eastern Time, unless postponed or adjourned to a later date.